A b s t r a c t
Merkel cell carcinoma (MCC) is a rare, aggressive, primary neuroendocrine carcinoma of the skin that has characteristic morphologic and immunophenotypic features. The incidence of MCCs is on the rise and has tripled since 1986. 1, 2 MCCs are usually found on sun-exposed sites, such as the head and neck region and upper extremities, but they can occur almost anywhere. UV radiation and immunosuppression have been implicated in the pathogenesis of MCCs, with recent reports demonstrating a 13-fold increased risk for MCC in patients with HIV infection. [3] [4] [5] The majority of MCCs are found in elderly people, with a median age at diagnosis of 69 years. 1 MCCs have variable manifestations, but they most commonly appear as solitary purple to red nodules or plaques, especially in the early stages of the lesion. 6, 7 Morphologically, MCCs are composed of small round blue cells, with minimal cytoplasm, within the dermis and/or subcutis ❚Image 1❚. 8 Cytologically, the tumor cells have pale or dense hyperchromatic nuclei with a finely granular chromatin pattern. Tumor cells can often show nuclear molding and associated crush artifact. The differential diagnosis includes other tumors with small round blue cell morphologic features, such as melanoma and lymphoma, but more important, small cell lung carcinoma (SCLC). SCLC may have nearly identical histopathologic features and aggressive clinical behavior. Once a diagnosis of MCC has been made, it is recommended that the patient be screened to exclude metastatic SCLC. 9 Immunohistochemical analysis is valuable in the evaluation and differentiation of MCC and SCLC. MCCs are reactive with antibodies to cytokeratins (CKs), such as low-molecular-weight CK7 and CK20, which stains in Upon completion of this activity you will be able to:
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a characteristic paranuclear dot-like pattern. 10, 11 Similar to SCLCs, most MCCs are also positive for the neuroendocrine markers chromogranin, synaptophysin, and CD56. In contrast with MCCs, SCLCs demonstrate high expression of thyroid transcription factor (TTF)-1 and CK7. [12] [13] [14] [15] [16] Recently, nuclear reactivity with terminal deoxynucleotidyl transferase (TdT) has been described in MCCs. 17, 18 TdT is a DNA polymerase found in mammals that catalyzes the elongation of nucleotide chains. Its actions are greatest in developing early B cells and T cells during immunoglobulin and T-cell receptor rearrangements, respectively. Lymphoblastic lymphoma/leukemia and acute myeloid leukemia, as well as medulloblastoma, Ewing sarcoma, and pediatric rhabdomyosarcoma, have nuclear expression of TdT. [19] [20] [21] Studies by Sur et al 17 TdT expression in SCLC remains unknown, and its expression might be useful in distinguishing MCC from SCLC. The aim of our study was to evaluate a group of cases of MCC, SCLC, and pulmonary carcinoid tumors (PCT) with the use of immunohistochemical markers for TdT, TTF-1, CK7, CK20, chromogranin, and synaptophysin.
Materials and Methods
The study was approved by the Sunnybrook Health Sciences Centre Ethics Review Board, Toronto, Canada. All patients were seen at or sought consultations from physicians at Sunnybrook Health Sciences Centre. We studied 40 cases of MCC, 30 cases of SCLC, and 6 cases of PCT accessioned during the 1995-2009 period in the Department of Anatomic Pathology, Sunnybrook Health Sciences Centre. Pertinent demographic and clinical data were retrieved from the electronic medical records.
Widely accepted criteria on H&E-stained sections in conjunction with immunohistochemical studies were used to make the diagnosis, and only clear-cut cases were selected. Cases were reviewed by 2 pathologists (Z.G. and S.J.R.) and 1 dermatopathologist (W.H.) who selected a block containing representative tumor for immunohistochemical studies. These studies were performed on formalin-fixed, paraffin-embedded tissue sections using a panel of antibodies raised against TdT, TTF-1, CK7, CK20, chromogranin, and synaptophysin. Immunostaining was performed on a DAKO Autostainer (DAKO, Carpinteria, CA) using a polymer detection system. The primary antibodies that were used, including dilutions and antigen-retrieval methods, are listed in ❚Table 1❚.
The stained slides were assessed for TdT reactivity as follows: reactivity in fewer than 1% of tumor cells was scored as negative, reactivity in 1% to 25% of cells as +, reactivity in 26% to 50% of cells as 2+, and reactivity in more than 50% of cells as 3+. Nuclear staining was evaluated by using a 3-tiered scale (weak, moderate, or strong). Two pathologists reviewed and scored all cases (Z.G. and S.J.R.). All original slides were reviewed to confirm the diagnoses. The majority of cases and immunohistochemical markers had easily identifiable internal positive control samples (epidermis and sweat gland epithelium). There were no significant differences in reactivity or distribution of staining by anatomic site.
Note was taken of all clinical information available from patient charts, including imaging studies, up until the time of our study. Patients with a definite diagnosis of MCC were thought to include cases that had negative imaging studies and no evidence of a primary lung lesion at the time of diagnosis or the presence of regional nodal metastases. All SCLC cases had supportive clinical and imaging findings.
Results

Clinical Data
A total of 40 MCCs, 30 SCLCs, and 6 PCTs were selected and analyzed. Of the 40 MCC patients, 25 (63%) were men and 15 (38%) were women, ranging in age from 59 to 95 years (mean, 78.3 years). Of the MCC tumors, 12 (30%) were from the head and neck, 3 (8%) from the trunk, 6 (15%) from the upper extremity, and 17 (43%) from the lower extremity; 2 (5%) manifested as metastasis (lymph node and liver). (33%) were men and 4 (67%) were women, ranging in age from 53 to 92 years (mean, 69.0 years). Five cases were from the right lung, and the remaining case was from the carina. ❚Table 3❚ shows the clinical data.
Immunohistochemical Studies
The immunohistochemical data for all cases studied are summarized in Tables 2 and 3 and ❚Table 4❚. The evaluation of immunohistochemical studies by method was based on the overall expression of the antibodies in the tumor. In all cases, reactivity was diffuse, demonstrating a mixed population of positive and negative cells with no variability seen by region of the tumor.
Terminal Deoxynucleotidyl Transferase
Of 40 MCC cases, 28 (70%) were positive for TdT with nuclear staining (Tables 2 and 4 ) ❚Image 2❚ and ❚Image 3❚. Of the 40 cases, 16 (40%) demonstrated moderate TdT staining intensity, whereas 8 (20%) showed weak and 4 (10%) showed strong nuclear TdT staining intensity. In 12 cases, there was no positive staining for TdT. In 15 (38%) of 40 MCC cases, 25% to 50% of tumor cells were reactive to TdT. Reactivity to TdT in more than 50% of tumor cells was seen in only 2 (5%) of 40 cases, whereas 11 (28%) of 40 had reactivity in fewer than 25% of tumor cells.
Of 30 SCLC cases, 2 (7%) were positive for TdT ❚Image 4❚. Both cases showed moderate nuclear TdT staining intensity in fewer than 25% of tumor cells (Table 3) . Immunohistochemical studies showed no positive staining for TdT in PCTs (0/6).
Thyroid Transcription Factor 1
Of the 40 MCC cases, 1 (3%) was positive for TTF-1. The positive MCC case showed weak TTF-1 nuclear staining intensity, with fewer than 25% of tumor cells reactive (Table 4 ). Moderate to strong nuclear staining for TTF-1 was seen in 23 (77%) of 30 SCLC cases and 4 (67%) of 6 PCT cases (Table 3 ). More than 50% of tumor cells were reactive in all cases.
Cytokeratins 7 and 20
Of 40 MCC cases, 2 (5%) were positive for CK7, with moderate cytoplasmic staining in 25% to 50% of tumor cells. In 35 (88%) of 40 MCC cases, there was positivity for CK20 with typical paranuclear dot-like and membranous positivity ❚Image 5❚. More than 50% of tumor cells were positive, and the staining intensity was strong for CK20 in all positive MCC cases (Tables 2 and 4) .
Of 30 SCLC cases, 22 (73%) were positive for CK7, showing strong cytoplasmic staining intensity and reactivity in more than 50% of tumor cells. None of the SCLC or PCT cases was positive for CK20. Only 1 (17%) of 6 PCTs was positive for CK7. Staining for CK7 was cytoplasmic and moderate in intensity, with 25% to 50% of tumor cells reactive (Tables 3 and 4) .
Chromogranin and Synaptophysin
Of the 40 MCC cases, 29 (73%) and 39 (98%) were positive for chromogranin and synaptophysin, respectively (Table 4) 
Discussion
MCC is an uncommon skin tumor that tends to affect the elderly population, with a reported tripling in its incidence during the last 20 years. 1, 2 MCCs have been associated with sun damage and immunosuppression and are aggressive tumors with a poor prognosis. [3] [4] [5] Diagnosis of MCCs can be difficult because many other tumors can appear histologically similar. MCCs are composed of small round blue cells forming sheets with hyperchromatic nuclei, inconspicuous nucleoli, and minimal cytoplasm. The differential diagnosis includes other small round blue cell tumors, such as basal cell carcinoma, lymphoma, melanoma, cutaneous Ewing sarcoma, and metastatic SCLC. Numerous panels of immunohistochemical stains are essential in excluding these MCC imitators; however, SCLC is much more difficult because both tumors have some overlapping immunohistochemical and histologic features. [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, similar to MCCs, SCLCs are very aggressive neuroendocrine cancers with a high mortality. Numerous studies have demonstrated that MCCs and SCLCs show comparable genetic alterations. [22] [23] [24] Differentiating MCC from SCLC is difficult but crucial for appropriate patient management and prognosis.
Typically, MCCs are positive for CK20 and negative for TTF-1, whereas SCLCs are positive usually for CK7 and TTF-1. [10] [11] [12] [13] [14] [15] [25] [26] [27] However, many exceptions exist, and these patterns are often variable with overlap between MCCs and SCLCs. 13 Up to 20% of SCLCs may be negative for TTF-1, and TTF-1 usually does not stain MCCs, but rare cases have been reported. 28 Moreover, many reports have demonstrated that SCLCs can be positive for CK20 and some MCCs may be positive for CK7, in addition to CK20. 29, 30 A few markers can help clear this confusion. One such marker is neurofilament. 31 Neurofilament is positive in MCCs but is consistently negative in SCLCs. Unfortunately, neurofilament is not always expressed in MCCs.
Recently, Feng et al 28 TdT is a nuclear protein that seems to be expressed in a large proportion of MCCs. The results of our study on a relatively large number of MCC cases are similar to previous observations regarding the frequent expression and nuclear reactivity of TdT in MCC. 21, 22 In the present study, 70% of MCC cases exhibited TdT positivity, with most cases demonstrating more than 25% of tumor cells reactive for TdT with moderate to strong nuclear intensity. It is interesting that 2 of the 30 SCLCs demonstrated TdT positivity, with fewer than 25% of tumor cells reactive and with moderate staining intensity. We further confirm the variable and often overlapping immunohistochemical results between MCCs and SCLCs because all markers, including TdT but with the exception of CK20, were positive in both tumors. In 1 MCC case (3%), there was positivity for TTF-1, and 2 cases (5%) were also positive for CK7, while 77% of SCLCs were positive for TTF-1 and 73% of SCLCs were also positive for CK7. Synaptophysin and chromogranin were commonly expressed in both MCC and SCLC.
CK20 is considered to be the most specific and sensitive marker for MCC. The majority of MCC cases in our study were positive for CK20 (35/40 [88%]), demonstrating typical paranuclear dot-like and membranous positivity. Although 
